Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"Safety and Tolerability of Neoadjuvant Nivolumab for Locally Advanced Resectable Oral Cancer Combined With [18F] BMS-986192 / [18F] -FDG PET Imaging and Immunomonitoring for Response Prediction"

NCT03843515 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.

NCT NCT03843515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03843515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"Safety and Tolerability of Neoadjuvant Nivolumab for Locally Advanced Resectable Oral Cancer Combined With [18F] BMS-986192 / [18F] -FDG PET Imaging and Immunomonitoring for Response Prediction"
Lead sponsor
Amsterdam UMC, location VUmc
Phase
Phase 1
Overall status
Unknown status
Start date
April 11, 2019
Completion date
August 31, 2022
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oral cavity squamous cell carcinoma